Antireflux surgery for Barrett's oesophagus

ANZ Journal of Surgery

Volumn 73, Issue 4, 2003, Pages 234-236

  Lord, Reginald V N ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anti reflux surgery; Barrett's oesophagus; Fundoplication; Gastro oesophageal reflux disease; Oesophageal adenocarcinoma

Indexed keywords

ANALGESIA; ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CANCER; DISEASE COURSE; DISEASE SEVERITY; DUODENUM TUMOR; DYSPLASIA; FOLLOW UP; HUMAN; INTESTINE METAPLASIA; REDUCTION; REGRESSION ANALYSIS; RELIABILITY; REVIEW; SURGICAL TECHNIQUE;

EID: 0038703678     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-1433.2003.02569.x     Document Type: Review

References (249)

1. McClave SA, Boyce HJ, Gottfried MR. Early diagnosis of columnar-lined esophagus: A new endoscopic diagnostic criterion. Gastrointest. Endosc. 1987; 33: 413-16.
2. Öberg S, Peters JH, DeMeester TR et al. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann. Surg. 1997; 226: 522-30.
3. GOSPE. Barrett's Esophagus: Epidemiological and clinical results of multicentric survey. Int. J. Cancer 1991; 48: 364-8.
4. Winters CJ, Spurling TJ, Chobanian SJ et al. Barrett's esophagus: A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-24.
5. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N. Engl. J. Med. 1985; 313: 857-9.
6. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J. Gastroenterol. 1997; 92: 1293-7.
7. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus: Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99: 918-22.
8. Ormsby AH, Kilgore SP, Goldblum JR, Richter JE, Rice TW, Gramlich TL. The location and frequency of intestinal metaplasia at the esophagogastric junction in 223 consecutive autopsies: Implications for patient treatment and preventive strategies in Barrett's esophagus. Mod. Pathol. 2000; 13: 614-20.
9. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123: 461-7.
10. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: A prospective controlled investigation. Am. J. Med. 2001; 111: 33-7.
11. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: Observational study. BMJ 2000; 321: 1252-5.
12. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-8.
13. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's Esophagus Registry. Am. J. Gastroenterol. 1999; 94: 2037-42.
14. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am. J. Gastroenterol. 1997; 92: 212-15.
15. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett's oesophagus: An important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33: 1155-8.
16. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991; 32: 1441-6.
17. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-56.
18. Bonelli L. Barrett's esophagus: Results of a multicentric survey. G.O.S.P.E. (Gruppo Operativo per lo Studio delle Precancerosi Esofagee). Endoscopy 1993; 25: 652-4.
19. Tytgat GNJ. Does endoscopic surveillance in esophageal columnar metaplasia have any real value? Endoscopy 1995; 27: 19-26.
20. Zhuang Z, Vortmeyer AO, Mark EJ et al. Barrett's esophagus: Metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Cancer Res. 1996; 56: 1961-4.
21. Walch AK, Zitzelsberger HF, Bruch J et al. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasiadysplasia-carcinoma sequence. Am. J. Pathol. 2000; 156: 555-66.
22. Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Weber JL, Russell SE. Barrett's oesophagus: Microsatellite analysis provides evidence to support the proposed metaplasia-dysplasiacarcinoma sequence. Genes Chromosomes Cancer 1998; 21: 49-60.
23. Lord RVN, DeMeester TR. Reflux disease and hiatal hernia. In: Morris PJ, Wood WC (eds) Oxford Textbook of Surgery. Oxford: Oxford University Press, 2000; 1239-62.
24. Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am. J. Gastroenterol. 1997; 92: 27-31.
25. Cameron AJ. Barrett's esophagus: Prevalence and size of hiatal hernia. Am. J. Gastroenterol. 1999; 94: 2054-9.
26. Oberg S, Ritter MP, Crookes PF et al. Gastroesophageal reflux disease and mucosal injury with emphasis on short-segment Barrett's esophagus and duodenogastroesophageal reflux. J. Gastrointest. Surg. 1998; 2: 547-53.
27. Fass R, Hell RW, Garewal HS et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 2001; 48: 310-13.
28. Skinner DB, Walther BC, Riddell RH, Schmidt H, Iascone C, DeMeester TR. Barrett's esophagus. Comparison of benign and malignant cases. Ann. Surg. 1983; 198: 554-65.
29. DeMeester TR, Peters JH, Bremner CG, Chandrasoma P. Biology of gastroesophageal reflux disease: Pathophysiology relating to medical and surgical treatment. Annu. Rev. Med. 1999; 50: 469-506.
30. Parrilla P, Ortiz A, Martinez de Haro LF, Aguayo JL, Ramirez P. Evaluation of the magnitude of gastro-oesophageal reflux in Barrett's oesophagus. Gut 1990; 31: 964-7.
31. Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett's esophagus. Functional assessment, proposed pathogenesis, and surgical therapy. Arch. Surg. 1983; 118: 543-9.
32. Attwood SE, DeMeester TR, Bremner CG, Barlow AP, Hinder RA. Alkaline gastroesophageal reflux: Implications in the development of complications in Barrett's columnar-lined lower esophagus. Surgery 1989; 106: 764-70.
33. Gillen P, Keeling P, Byrne PJ, Hennessy TP. Barrett's oesophagus: pH profile. Br. J. Surg. 1987; 74: 774-6.
34. Stein HJ, Hoeft S, DeMeester TR. Functional foregut abnormalities in Barrett's esophagus. J. Thorac. Cardiovasc. Surg. 1993; 105: 107-11.
35. Öberg S, DeMeester TR, Peters JH et al. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J. Thorac. Cardiovasc. Surg. 1999; 117: 572-80.
36. Stein HJ, Barlow AP, DeMeester TR, Hinder RA. Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux. Ann. Surg. 1992; 216: 35-43.
37. Singh P, Taylor RH, Colin-Jones DG. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present. Am. J. Gastroenterol. 1994; 89: 349-56.
38. DeMeester TR, Attwood SE, Smyrk TC, Therkildsen DH, Hinder RA. Surgical therapy in Barrett's esophagus. Ann. Surg. 1990; 212: 528-40.
39. Mason RJ, Bremner CC. Motility differences between longsegment and short-segment Barrett's esophagus. Am. J. Surg. 1993; 165: 686-9.
40. Campos GM, Peters JH, DeMeester TR, Oberg S, Crookes PF, Mason RJ. The pattern of esophageal acid exposure in gastroesophageal reflux disease influences the severity of the disease. Arch. Surg. 1999; 134: 882-7.
41. Gillen P, Keeling P, Byrne PJ, Healy M, O'Moore RR, Hennessy TP. Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus. Br. J. Surg. 1988; 75: 540-3.
42. Attwood SE, Smyrk TC, DeMeester TR, Mirvish SS, Stein HJ, Hinder RA. Duodenoesophageal reflux and the development of esophageal adenocarcinoma in rats. Surgery 1992; 111: 503-10.
43. Iftikhar SY, Ledingham S, Steele RJ et al. Bile reflux in columnar-lined Barrett's oesophagus. Ann. R. Coll. Surg. Engl. 1993; 75: 411-16.
44. Stein HJ, Feussner H, Kauer W, DeMeester TR, Siewert JR. Alkaline gastroesophageal reflux: assessment by ambulatory esophageal aspiration and pH monitoring. Am. J. Surg. 1994; 167: 163-8.
45. Kauer WK, Burdiles P, Ireland AP et al. Does duodenal juice reflux into the esophagus of patients with complicated GERD? Evaluation of a fiberoptic sensor for bilirubin. Am. J. Surg. 1995; 169: 98-103.
46. Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann. Surg. 1995; 222: 525-31.
47. Champion G, Richter JE, Vaezi MF, Singh S, Alexander R. Duodenogastroesophageal reflux: Relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994; 107: 747-54.
48. Caldwell MT, Lawlor P, Byrne PJ, Walsh TN, Hennessy TP. Ambulatory oesophageal bile reflux monitoring in Barrett's oesophagus. Br. J. Surg. 1995; 82: 657-60.
49. Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: Influence of gastric acidity. Gut 1999; 44: 598-602.
50. Nehra D, Howell P, Pye JK, Beynon J. Assessment of combined bile acid and pH profiles using an automated sampling device in gastro-oesophageal reflux disease. Br. J. Surg. 1998; 85: 134-7.
51. Fein M, Ireland AP, Ritter MP et al. Duodenogastric reflux potentiates the injurious effects of gastroesophageal reflux. J. Gastrointest. Surg. 1997; 1: 27-33.
52. Liron R, Parrilla P, Martinez dHL et al. Quantification of duodenogastric reflux in Barrett's esophagus. Am. J. Gastroenterol. 1997; 92: 32-6.
53. Menges M, Muller M, Zeitz M. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am. J. Gastroenterol. 2001; 96: 331-7.
54. Gotley DC, Morgan AP, Ball D, Owen RW, Cooper MJ. Composition of gastro-oesophageal refluxate. Gut 1991; 32: 1093-9.
55. Clark GW, Smyrk TC, Mirvish SS et al. Effect of gastroduodenal juice and dietary fat on the development of Barrett's esophagus and esophageal neoplasia: An experimental rat model. Ann. Surg. Oncol. 1994; 1: 252-61.
56. Ireland AP, Peters JH, Smyrk TC et al. Gastric juice protects against the development of esophageal adenocarcinoma in the rat. Ann. Surg. 1996; 224: 358-70.
57. Fein M, Peters JH, Chandrasoma P et al. Duodenoesophageal reflux induces esophageal adenocarcinoma without exogenous carcinogen. J. Gastrointest. Surg. 1998; 2: 260-8.
58. Pera M, Cardesa A, Bombi JA, Ernst H, Pera C, Mohr U. Influence of esophagojejunostomy on the induction of adenocarcinoma of the distal esophagus in Sprague-Dawley rats by subcutaneous injection of 2,6-dimethylnitrosomorpholine. Cancer Res. 1989; 49: 6803-8.
59. Miwa K, Sahara H, Segawa M et al. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int. J. Cancer 1996; 67: 269-74.
60. Goldstein SR, Yang GY, Curtis SK et al. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 1997; 18: 2265-70.
61. Oberg S, Lord RV, Peters JH et al. Is adenocarcinoma following esophagoduodenostomy without carcinogen in the rat refluxinduced? J. Surg. Res. 2000; 91: 111-17.
62. Lord RV. The genetic basis of the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. Probl. Gen. Surg. 2001; 18: 53-70.
63. Barrett MT, Sanchez CA, Prevo LJ et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat. Genet. 1999; 22: 106-9.
64. Eads CA, Lord RV, Wickramasinghe K et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001; 61: 3410-18.
65. Eads CE, Lord RV, Kurumboor SK et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 2000; 60: 5021-6.
66. Krishnadath KK, Tilanus HW, van Blankenstein M et al. Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus. Cancer Res. 1995; 55: 1971-6.
67. Lauwers GY, Kandemir O, Kubilis PS, Scott GV. Cellular kinetics in Barrett's epithelium carcinogenic sequence: Roles of apoptosis, bcl-2 protein, and cellular proliferation. Mod. Pathol. 1997; 10: 1201-8.
68. Neshat K, Sanchez CA, Galipeau PC et al. Barrett's esophagus: A model of human neoplastic progression. Cold Spring Harb. Symp. Quant. Biol. 1994; 59: 577-83.
69. Riegman PH, Vissers KJ, Alers JC et al. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res. 2001; 61: 3164-70.
70. Lord RV, O'Grady R, Sheehan C, Field AF, Ward RL. K-ras codon 12 mutations in Barrett's oesophagus and Barrett's associated adenocarcinomas. J. Gastroenterol. Hepatol. 2000; 15: 730-6.
71. Kawakami K, Brabender J, Lord RV et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl Cancer Inst. 2000; 92: 1805-11.
72. Ireland AP, Shibata D, Chandrasoma P, Lord RV, Peters JH, DeMeester TR. The clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann. Surg. 2000; 231: 179-87.
73. Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 1998; 83: 652-9.
74. Lord RV, Salonga D, Danenberg KD et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J. Gastrointest. Surg. 2000; 4: 135-42.
75. Soslow RA, Ying L, Altorki NK. Expression of acidic fibroblast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma. J. Thorac. Cardiovasc. Surg. 1997; 114: 838-43.
76. Lord RV, Park JM, Danenberg KD et al. Increase in vascular endothelial growth factor and basic fibroblast growth factor expression in Barrett's esophagus and adenocarcinomas of the esophagus and gastroesophageal junction. J. Thorac. Cardiovasc. Surg. 2000; 25: 246-53.
77. Spechler SJ. Medical treatment of Barrett's esophagus. J. Gastrointest. Surg. 2000; 4: 119-21.
78. Lundell L. Acid suppression in the long-term treatment of peptic stricture and Barrett's oesophagus. Digestion 1992; 51: 49-58.
79. Klinkenberg-Knol EC, Festen HP, Jansen JB et al. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety. Ann. Intern. Med. 1994; 121: 161-7.
80. Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am. J. Gastroenterol. 1996; 91: 1749-57.
81. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment. Pharmacol. Ther. 1998; 12: 1235-40.
82. Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment. Pharmacol. Ther. 1998; 12: 1231-4.
83. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9.
84. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J. Clin. Invest. 1996; 98: 2120-8.
85. Lord RVN, Peters JH. Surgical therapy for Barrett's esophagus. In: Sharma P, Sampliner RE (eds) Barrett's Esophagus and Esophageal Adenocarcinoma. Malden, MA: Blackwell Science, 2001; 181-97.
86. Johnson DA, Winters C, Spurling TJ, Chobanian SJ, Cattau EJ. Esophageal acid sensitivity in Barrett's esophagus. J. Clin. Gastroenterol. 1987; 9: 23-7.
87. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am. J. Gastroenterol. 1994; 89: 1844-8.
88. Bammer T, Hinder RA, Klaus A, Klingler PJ. Five- to eight-year outcome of the first laparoscopic Nissen fundoplications. J. Gastrointest. Surg. 2001; 5: 42-8.
89. Lafullarde T, Watson DI, Jamieson GG, Myers JC, Game PA, Devitt PG. Laparoscopic Nissen fundoplication: Five-year results and beyond. Arch. Surg. 2001; 136: 180-4.
90. Gotley DC, Smithers BM, Rhodes M, Menzies B, Branicki FJ, Nathanson L. Laparoscopic Nissen fundoplication: 200 consecutive cases. Gut 1996; 38: 487-91.
91. Orringer MB, Skinner DB, Belsey RHR. Long-term results of the Mark IV operation for hiatal hernia and analyses of recurrences and their treatment. J. Thorac. Cardiovasc. Surg. 1972; 63: 25-31.
92. Luostarinen M, Isolauri J, Laitinen J et al. Fate of Nissen fundoplication after 20 years. A clinical, endoscopical, and functional analysis. Gut 1993; 34: 1015-20.
93. Richardson WS, Trus TL, Thompson S, Hunter JG. Nissen and Toupet fundoplications effectively inhibit gastroesophageal reflux irrespective of natural anatomy and function. Surg. Endosc. 1997; 11: 261-3.
94. Schwab GP, Blum AL, Bodner E et al. Gastro-oesophageal reflux disease: Medical or surgical treatment? Report of an interactive workshop. J. Gastroenterol. Hepatol. 1997; 12: 785-9.
95. Dallemagne B, Weerts JM, Jeahes C, Markiewicz S. Results of laparoscopic Nissen fundoplication. Hepatogastroenterology 1998; 45: 1338-43.
96. Rantanen TK, Salo JA, Sipponen JT. Fatal and life-threatening complications in antireflux surgery. Analysis of 5,502 operations. Br. J. Surg. 1999; 86: 1573-7.
97. Watson DI, Jamieson GG. Antireflux surgery in the laparoscopic era. Br. J. Surg. 1999; 85: 1173-84.
98. Eubanks TR, Omelanczuk P, Richards C, Pohl D, Pellegrini CA. Outcomes of laparoscopic antireflux procedures. Am. J. Surg. 2000; 179: 391-5.
99. Lundell L, Miettinen P, Myrvold HE et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J. Am. Coll Surg. 2001; 192: 172-9.
100. Mobius C, Stein HJ, Feith M, Feussner H, Siewert JR. Quality of life before and after laparoscopic Nissen fundoplication. Surg. Endosc. 2001; 15: 353-6.
101. Peters JH, DeMeester TR, Crookes P et al. The treatment of gastroesophageal reflux disease with laparoscopic Nissen fundoplication: Prospective evaluation of 100 patients with 'typical' symptoms. Ann. Surg. 1998; 228: 40-50.
102. Tins TL, Laycock WS, Waring JP, Branum GD, Hunter JG. Improvement in quality of life measures after laparoscopic antireflux surgery. Ann. Surg. 1999; 229: 331-6.
103. Glise H, Hallerback B, Johansson B. Quality-of-life assessments in evaluation of laparoscopic Rosetti fundoplication. Surg. Endosc. 1995; 9: 183-8.
104. Velanovich V, Vallance SR, Gusz JR, Tapia FV, Harkabus MA. Quality of life scale for gastroesophageal reflux disease. J. Am. Coll Surg. 1996; 183: 217-24.
105. Van Den Boom G, Go PM, Hameeteman W, Dallemagne B, Ament AJ. Cost effectiveness of medical versus surgical treatment in patients with severe or refractory gastroesophageal reflux disease in the Netherlands. Scand. J. Gastroenterol. 1996; 31: 1-9.
106. Viljakka M, Nevalainen J, Isolauri J. Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland. Scand. J. Gastroenterol. 1997; 32: 766-72.
107. Heudebert GR, Marks R, Wilcox CM, Centor RM. Choice of long-term strategy for the management of patients with severe esophagitis: A cost-utility analysis. Gastroenterology 1997; 112: 1078-86.
108. Lord RV, Bowrey DJ, Blom D. Barrett's esophagus: A surgical disease? Am. J. Gastroenterol. 2000; 95: 3302-5.
109. Behar J, Sheahan DG, Biancani P, Spiro HM, Storer EH. Medical and surgical management of reflux esophagitis. A 38-month report of a prospective clinical trial. N. Engl. J. Med. 1975; 293: 263-8.
110. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N. Engl. J. Med. 1992; 326: 786-92.
111. Costantini M, Zaninotto G, Anselmino M, Boccu C, Nicoletti L, Ancona E. The role of a defective lower esophageal sphincter in the clinical outcome of treatment for gastroesophageal reflux disease. Arch. Surg. 1996; 131: 655-9.
112. Isolauri J, Luostarinen M, Viljakka M et al. Long-term comparison of antireflux surgery versus conservative therapy for reflux esophagitis. Ann. Surg. 1997; 225: 295-9.
113. Spechler SJ, Lee E, Ahnen DJ et al. Long-term outcome of medical and surgical therapies for GERD: Effects on GERD symptoms and signs. Gastroenterology 2000; 118: A193.
114. Spechler SJ, Lee A, Ahnen D et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. JAMA 2001; 285: 2331-8.
115. Lord RV, Kaminski A, Oberg A et al. Absence of gastroesophageal reflux disease in a majority of patients taking acid suppression medications after Nissen fundoplication. J. Gastrointest. Surg. 2002; 6: 3-9.
116. Starnes VA, Adkins RB, Ballinger JF, Sawyers JL. Barrett's esophagus. A surgical entity. Arch. Surg. 1984; 119: 563-7.
117. Williamson WA, Ellis FJ, Gibb SP, Shahian DM, Aretz HT. Effect of antireflux operation on Barrett's mucosa. Ann. Thorac. Surg. 1990; 49: 537-41.
118. Attwood SE, Barlow AP, Norris TL, Watson A. Barrett's oesophagus: Effect of antireflux surgery on symptom control and development of complications. Br. J. Surg. 1992; 79: 1050-3.
119. Csendes A, Braghetto I, Burdiles P et al. Long-term results of classic antireflux surgery in 152 patients with Barrett's esophagus: Clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and late after operation. Surgery 1998; 126: 645-57.
120. Ortiz A, Martinez de Haro LF, Parrilla P et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: Long-term results of a prospective study. Br. J. Surg. 1996; 83: 274-8.
121. McDonald ML, Trastek VF, Allen MS, Deschamps C, Pairolero PC. Barretts's esophagus: Does an antireflux procedure reduce the need for endoscopic surveillance? J. Thorac. Cardiovasc. Surg. 1996; 111: 1135-8.
122. Farrell TM, Smith CD, Metreveli RE, Johnson AB, Galloway KD, Hunter JG. Fundoplication provides effective and durable symptom relief in patients with Barrett's esophagus. Am. J. Surg. 1999; 178: 18-21.
123. Chen LQ, Nastos D, Hu CY et al. Results of the Collis-Nissen gastroplasty in patients with Barrett's esophagus. Ann. Thorac. Surg. 1999; 68: 1014-20.
124. Patti MG, Arcerito M, Feo CV et al. Barrett's esophagus: A surgical disease. J. Gastrointest. Surg. 1999; 3: 397-404.
125. Yau P, Watson DI, Devitt PG, Game PA, Jamieson GG. Laparoscopic antireflux surgery in the treatment of gastroesophageal reflux in patients with Barrett esophagus. Arch. Surg. 2000; 135: 801-5.
126. Hofstetter WL, Peters JH, DeMeester TR et al. Long-term outcome of antireflux surgery in patients with Barrett's esophagus. Ann. Surg. 2001; 234: 532-8.
127. Csendes A, Burdiles P, Braghetto I et al. Dysplasia and adenocarcinoma after classic antireflux surgery in patients with Barrett's esophagus: The need for long-term subjective and objective follow-up. Ann. Surg. 2002; 235: 178-85.
128. Bell RC, Hanna P, Mills MR, Bowrey D. Patterns of success and failure with laparoscopic Toupet fundoplication. Surg. Endosc. 1999; 13: 1189-94.
129. Richardson JD, Richardson RL. Collis-Nissen gastroplasty for shortened esophagus: Long-term evaluation. Ann. Surg. 1998; 227: 735-40.
130. McEntee GP, Stuart RC, Byrne PJ, Nolan N, Hennessy TPJ. An evaluation of surgical and medical treatment of Barrett's oesophagus. Gullet 1991; 1: 169-72.
131. Stein HJ, Kauer WK, Feussner H, Siewert JR. Bile reflux in benign and malignant Barrett's esophagus: Effect of medical acid suppression and Nissen fundoplication. J. Gastrointest. Surg. 1998; 2: 333-41.
132. Heikkinen TJ, Haukipuro K, Bringman S, Ramel S, Sorasto A, Hulkko A. Comparison of laparoscopic and open Nissen fundoplication 2 years after operation. A prospective randomized trial. Surg. Endosc. 2000; 14: 1019-23.
133. Sontag SJ, Schnell TG, Chejfec G, Kurucar C, Karpf J, Levine G. Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus. Aliment. Pharmacol. Ther. 1997; 11: 147-56.
134. Klinkenberg-Knol EC, Nelis F, Dent J et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9.
135. El-Serag HB, Sonnenberg A. Outcome of erosive reflux esophagitis after Nissen fundoplication. Am. J. Gastroenterol. 1999; 94: 1771-6.
136. Spivak H, Farrell TM, Tins TL, Branum GD, Warring JP, Hunter JG. Laparoscopic fundoplication for dysphagia and peptic esophageal stricture. J. Gastrointest. Surg. 1998; 2: 555-60.
137. Klingler PJ, Hinder RA, Cina RA et al. Laparoscopic antireflux surgery for the treatment of esophageal strictures refractory to medical therapy. Am. J. Gastroenterol. 1999; 94: 632-6.
138. Bonavina L, Segalin A, Fumagalli U, Peracchia A. Surgical management of benign stricture from reflux oesophagitis. Ann. Chir. Gynaecol. 1995; 84: 175-8.
139. Lord RVN, DeMeester TR. Benign oesophageal strictures. In: Morris PJ, Wood WC (eds) Oxford Textbook of Surgery. Oxford: Oxford University Press, 2000; 1262-9.
140. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am. J. Gastroenterol. 1994; 89: 989-91.
141. Öberg S, Johansson J, Wenner J el al. Endoscopic surveillance of columnar-lined esophagus: Frequency of intestinal metaplasia detection and impact of antireflux surgery. Ann. Surg. 2001; 234: 619-26.
142. Sagar PM, Ackroyd R, Hosie KB, Patterson JE, Stoddard CJ, Kingsnorth AN. Regression and progression of Barrett's oesophagus after antireflux surgery. Br. J. Surg. 1995; 82: 806-10.
143. Horvath KD, Jobe BA, Herron DM, Swanstrom LL. The laparoscopic Toupet is an inadequate procedure for patients with severe reflux disease. J. Gastrointest. Surg. 1999; 3: 583-91.
144. Vela M, Camacho-Lobato L, Hatlebakk J, Katz PO, Castell DO. Effect of omeprazole (PPI) on ratio of acid to nonacid gastroesophageal reflux. Studies using simultaneous intraesophageal impedance and pH measurement. Gastroenterology 1999; 116: A1202.
145. Manifold DK, Marshall RE, Anggiansah A, Owen WJ. Effect of omeprazole on antrai duodenogastric reflux in Barrett oesophagus. Scand. J. Gastroenterol. 2000; 35: 796-801.
146. Cameron AJ, Lomboy CT. Barrett's esophagus: Age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103: 1241-5.
147. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am. J. Gastroenterol. 1997; 92: 2012-16.
148. Chen LQ, Hu CY, Gaboury L, Pera M, Ferraro P, Duranceau AC. Proliferative activity in Barrett's esophagus before and after antireflux surgery. Ann. Surg. 2001; 234: 172-80.
149. Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: An acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J. Thorac. Cardiovasc. Surg. 1975; 70: 826-35.
150. Haggitt RC, Tryzelaar J, Ellis FH, Colcher H. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am. J. Clin. Pathol. 1978; 70: 1-5.
151. Levine MS, Caroline D, Thompson JJ, Kressel HY, Laufer I, Herlinger H. Adenocarcinoma of the esophagus: Relationship to Barrett mucosa. Radiology 1984; 150: 305-9.
152. Hakansson HO, Johnsson F, Johansson J, Kjellen G, Walther B. Development of adenocarcinoma in Barrett's oesophagus after successful antireflux surgery. Eur. J. Surg. 1997; 163: 469-71.
153. Smith RR, Hamilton SR, Boitnott JK, Rogers EL. The spectrum of carcinoma arising in Barrett's esophagus. A clinicopathologic study of 26 patients. Am. J. Surg. Pathol. 1984; 8: 563-73.
154. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 1999; 340: 825-31.
155. DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus: Fifty years of controversy. Ann. Surg. 2000; 231: 303-21.
156. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort. Gastroenterology 1992; 102: 1212-19.
157. Levine DS, Haggitt RC, Irvine S et al. Natural history of high-grade dysplasia in Barrett's esophagus. Gastroenterology 1996; 110: A550.
158. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am. J. Gastroenterol. 1998; 93: 536-41.
159. DeMeester SR, Campos GM, DeMeester TR et al. The impact of an antireflux procedure on intestinal metaplasia of the cardia. Ann. Surg. 1998; 228: 547-56.
160. Low DE, Levine DS, Dail DH, Kozarek RA. Histological and anatomic changes in Barrett's esophagus after antireflux surgery. Am. J. Gastroenterol. 1999; 94: 80-5.
161. Baulieux J, Mabrut JY, Ducerf C et al. [Barrett's esophagus and antireflux surgery: A study of a series of 26 patients]. Chirurgie 1999; 124: 398-405.
162. Bammer T, Hinder RA, Klaus A, Trastek VF, Achem SR. Rationale for surgical therapy of Barrett esophagus. Mayo Clin. Proc. 2001; 76: 335-42.
163. Provenzaie D, Schmitt C, Wong JB. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am. J. Gastroenterol. 1999; 94: 2043-53.
164. Hinder RA, Perdikis G, Klinger PJ, DeVault KR. The surgical option for gastroesophageal reflux disease. Am. J. Med. 1997; 103: 144S-148S.
165. Castell DO. Comment on: Patti et al. Barrett's esophagus: A surgical disease. J. Gastrointest. Surg. 1999; 3: 404.
166. McCallum RW, Plepalle S, Davenport K et al. Role of antireflux surgery against dysplasia in Barrett's esophagus. Gastroenterology 1991; 100: A121.
167. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JJ. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995; 274: 474-7.
168. Colin-Jones DG, Langman MJ, Lawson DH, Logan RF, Paterson KR, Vessey MP. Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. Gut 1992; 33: 1280-4.
169. Colin-Jones DG, Langman MJ, Lawson DH, Logan RF, Paterson KR, Vessey MP. Post-cimetidine surveillance for up to ten years: Incidence of carcinoma of the stomach and oesophagus. QJM 1991; 78: 13-19.
170. Zhang ZF, Kurtz RC, Sun M et al. Adenocarcinomas of the esophagus and gastric cardia: Medical conditions, tobacco, alcohol, and socioeconomic factors. Cancer Epidemiol. Biomarkers Prev. 1996; 5: 761-8.
171. Hansson LE, Sparen P, Nyren O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int. J. Cancer 1993; 54: 402-7.
172. Powell J, McConkey CC. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur. J. Cancer Prev. 1992; 1: 265-9.
173. Lord RV, Law MG, Ward RL, Giles GG, Thomas RJ, Thursfield V. Rising incidence of oesophageal adenocarcinoma in men in Australia. J. Gastroenterol. Hepatol. 1998; 13: 356-62.
174. Ye W, Chow WH, Lagergren J, Yin L, Nyren O. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001; 121: 1286-93.
175. Peters FT, Ganesh S, Kuipers EJ et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999; 45: 489-94.
176. Srinivasan R., Ramakrishnan A, Katzka DA, Katz PO, Castell DO. Effect of maximal acid reflux control on Barrett's esophagus (BE). Am. J. Gastroenterol. 1999; 94: A2600.
177. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. Am. J. Gastroenterol. 1999; 94: 3420-6.
178. Brand DL, Ylvisaker JT, Gelfand M, Pope CE. Regression of columnar esophageal (Barrett's) epithelium after anti-reflux surgery. N. Engl. J. Med. 1980; 302: 844-8.
179. Hassall E, Weinstein WM. Partial regression of childhood Barrett's esophagus after fundoplication. Am. J. Gastroenterol. 1992; 87: 1506-12.
180. Sampliner RE, Garewal HS, Fennerty MB, Aickin M. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig. Dis. Sci. 1990; 35: 93-6.
181. Neumann CS, Iqbal TH, Cooper BT. Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment.
182. Luostarinen ME, Mattila JJ, Auvinen OL, Matikainen MJ, Isolauri JO. Histological improvement of oesophagitis after Nissen fundoplication. Ann. Med. 1998; 30: 547-52.
183. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am. J. Gastroenterol. 1997; 92: 582-5.
184. Sampliner RE. New treatments for Barrett's esophagus. Semin. Gastrointest. Dis. 1997; 8: 68-74.
185. Wesdorp IC, Bartelsman J, Schipper ME, Tytgat GN. Effect of long-term treatment with cimetidine and antacids in Barrett's oesophagus. Gut 1981; 22: 724-7.
186. Johansson J, Johnsson F, Joelsson B, Floren CH, Walther B. Outcome 5 years after 360 degree fundoplication for gastrooesophageai reflux disease. Br. J. Surg. 1993; 80: 46-9.
187. El-Serag HB. Barrett's esophagus, hiatal hernia, and logistic regression analysis. Am. J. Gastroenterol. 1999; 94: 3395-6.
188. Gore S, Healey CJ, Sutton R et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment. Pharmacol. Ther. 1993; 7: 623-8.
189. Bologna SD, Blumenkehl M, Wong D et al. Barrett's esophagus response to long term omeprazole therapy. Gastrointest. Endosc. 1992; 38: A229.
190. Wellinger J, Ollyo JB, Savary M, Fontolliet C, Chapuis G. [Surgical treatment of Barrett esophagus. Apropos of 110 cases]. Helv. Chir. Acta 1989; 55: 695-8.
191. Martinez de Haro LF, Ortiz A, Parrilla P, Garcia MJ, Aguayo JL, Morales G. Long-term results of Nissen fundoplication in reflux esophagitis without strictures. Clinical, endoscopic, and pH-metric evaluation. Dig. Dis. Sci. 1992; 37: 523-7.
192. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-35.
193. Csendes A, Braghetto I, Burdiles P, Diaz JC, Maluenda F, Korn O. A new physiologic approach for the surgical treatment of patients with Barrett's esophagus: Technical considerations and results in 65 patients. Ann. Surg. 1997; 226: 123-33.
194. Levine DS, Haggitt RC, Rabinovitch PS et al. Complete regression of high-grade dysplasia, DNA content abnormalities and Barrett's esophagus. Gastroenterology 1996; 108: A496.
195. Schnell TG, Sontag SJ, Chejfec G et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120: 1607-19.
196. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett's high-grade dysplasia. Am. J. Gastroenterol. 2000; 95: 1888-93.
197. Montgomery E, Goldblum JR, Greenson JK et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study. Ham. Pathol. 2001; 32: 379-88.
198. Wetscher GJ, Gadenstaetter M, Klingler PJ et al. Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease. Ann. Surg. 2001; 234: 627-32.
199. Wetscher GJ, Profanter C, Gadenstatter M, Perdikis G, Glaser K, Hinder RA. Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor esophageal body motility. Langenbecks Arch. Chir. 1997; 382: 95-9.
200. Watson DI, de Beaux AC. Complications of laparoscopic antireflux surgery. Surg. Endosc. 2001; 15: 344-52.
201. Sandbu R, Khamis H, Gustavsson S, Haglund U. Long-term results of antireflux surgery indicate the need for a randomized clinical trial. Br. J. Surg. 2002; 89: 225-30.
202. Luostarinen M, Virtanen J, Koskinen M, Matikainen M, Isolauri J. Dysphagia and oesophageai clearance after laparoscopic versus open Nissen fundoplication. A randomized, prospective trial. Scand. J. Gastroenterol. 2001; 36: 565-71.
203. Nilsson G, Larsson S, Johnsson F. Randomized clinical trial of laparoscopic versus open fundoplication: Evaluation of psychological well-being and changes in everyday life from a patient perspective. Scand. J. Gastroenterol. 2002; 37: 385-91.
204. Nilsson G, Larsson S, Johnsson F. Randomized clinical trial: Randomized clinical trial of laparoscopic versus open fundoplication: blind evaluation of recovery and discharge period. Br. J. Surg. 2000; 87: 873-8.
205. Wenner J, Nilsson G, Oberg S, Melin T, Larsson S, Johnsson F. Short-term outcome after laparoscopic and open 360 degrees fundoplication. A prospective randomized trial. Surg. Endosc. 2001; 15: 1124-8.
206. Bais JE, Bartelsman JF, Bonjer HJ et al. Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: Randomised clinical trial. The Netherlands Antireflux Surgery Study Group. Lancet 2000; 355: 170-4.
207. Laine S, Rantala A, Gullichsen R, Ovaska J. Laparoscopic vs conventional Nissen fundoplication. A prospective randomized study. Surg. Endosc. 1997; 11: 441-4.
208. Blomqvist A, Lonroth H, Dalenback J, Ruth M, Wiklund I, Lundell L. Quality of life assessment after laparoscopic and open fundoplications. Results of a prospective, clinical study. Scand. J. Gastroenterol. 1996; 31: 1052-8.
209. Jobe BA, Wallace J, Hansen PD, Swanstrom LL. Evaluation of laparoscopic Toupet fundoplication as a primary repair for all patients with medically resistant gastroesophageal reflux, Surg. Endosc. 1997; 11: 1080-3.
210. Galmiche JP, Lehur PA, Bruley des Varannes S, Denis P. Twenty-four hour intraesophageal pH monitoring (Letter). Gastroenterology 1986; 91: 1581-3.
211. Ritter MP, Peters JH, DeMeester TR et al. Treatment of advanced gastroesophageal reflux disease with Collis gastroplasty and Belsey partial fundoplication. Arch. Surg. 1998; 133: 523-8.
212. Watson DI, Mathew G, Pike GK, Jamieson GG. Comparison of anterior, posterior and total fundoplication using a viscera model. Dis. Esoph. 1997; 10: 110-14.
213. Anderson JA, Myers JC, Watson DI, Gabb M, Mathew G, Jamieson GG. Concurrent fluoroscopy and manometry reveal differences in laparoscopic Nissen and anterior fundoplication. Dig. Dis. Sci. 1998; 43: 847-53.
214. Richardson WS, Hunter JG. The 'floppy' Nissen fundoplication is a completely competent antireflux valve. Surg. Endosc. 1999; 13: 142-5.
215. DeMeester TR, Johnson LF, Kent AH. Evaluation of current operations for the prevention of gastroesophageal reflux. Ann. Surg. 1974; 180: 511-25.
216. Jamieson GG, Watson DI. Optimal surgical therapy for anti reflux disease. In: Tilanus HW, Attwood SEA (eds) Barrett's Esophagus. Dordrecht: Kluwer Academic Publishers, 2001; 137-47.
217. Thor KB, Silander T. A long-term randomized prospective trial of the Nissen procedure versus a modified Toupet technique. Ann. Surg. 1989; 210: 719-24.
218. Lundell L, Abrahamsson H, Ruth M, Rydberg L, Lonroth H, Olbe L. Long-term results of a prospective randomized comparison of total fundic wrap (Nissen-Rossetti) or semifundoplication (Toupet) for gastro-oesophageal reflux. Br. J. Surg. 1996; 83: 830-5.
219. Watson DI, Mathew G, Pike GK, Baigrie RJ, Jamieson GG. Efficacy of anterior, posterior and total fundoplication in an experimental model. Br. J. Surg. 1998; 85: 1006-9.
220. Watson DI, Jamieson GG, Pike GK, Davies N, Richardson M, Devitt PG. Prospective randomized double-blind trial between laparoscopic Nissen fundoplication and anterior partial fundoplication. Br. J. Surg. 1999; 86: 123-30.
221. Walker SJ, Holt S, Sanderson CJ, Stoddard CJ. Comparison of Nissen total and Lind partial transabdominal fundoplication in the treatment of gastro-oesophageal reflux. Br. J. Surg. 1992; 79: 410-14.
222. Watson A, Jenkinson LR, Ball CS, Barlow AP, Norris TL. A more physiological alternative to total fundoplication for the surgical correction of resistant gastro-oesophageal reflux. Br. J. Surg. 1991; 78: 1088-94.
223. Peters JH. The surgical management of Barrett's esophagus. Gastroenterol. Clin. North Am. 1997; 26: 647-68.
224. Hunter JG, Tins TL, Branum GD, Waring JP, Wood WC. A physiologic approach to laparoscopic fundoplication for gastroesophageai reflux disease. Ann. Surg. 1996; 223: 673-85.
225. Rydberg L, Ruth M, Abrahamsson H, Lundell L. Tailoring antireflux surgery: A randomized clinical trial. World J. Surg. 1999; 23: 612-18.
226. Fibbe C, Layer P, Keller J, Strate U, Emmermann A, Zornig C. Esophageal motility in reflux disease before and after fundoplication: A prospective, randomized, clinical, and manometric study. Gastroenterology 2001; 121: 5-14.
227. Baigrie RJ, Watson DI, Myers JC, Jamieson GG. Outcome of Laparoscopic Nissen fundoplication in patients with disordered preoperative peristalsis. Gut 1997; 40: 381-5.
228. Beckingham IJ; Cariem AK, Bornman PC, Callanan MD, Louw JA. Oesophageal dysmotility is not associated with poor outcome after iaparoscopic Nissen fundoplication. Br. J. Surg. 1998; 85: 1290-3.
229. Puhalla H, Lenglinger J, Bischof G, Miholic J, Fugger R, Stacher G. [Nissen and Toupet laparoscopic fundoplication in patients with gastroesophageal reflux and motility disorders of the distal esophagus]. Chirurg 2002; 73: 230-4.
230. Heider TR, Farrell TM, Kircher AP, Colliver CC, Koruda MJ, Behrns KE. Complete fundoplication is not associated with increased dysphagia in patients with abnormal esophageal motility. J. Gastrointest. Surg. 2001; 5: 36-41.
231. Heading RC. Should abnormal oesophageal motility in gastrooesophageal reflux disease (GORD) influence decisions about fundoplication? Gut 2002; 50: 592-3.
232. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's muitifocal high-grade dysplasia or adenocarcinoma. Am. J. Gastroenterol. 1999; 94: 3413-9.
233. Williamson WA, Ellis FJ, Gibb SP et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch. Intern. Med. 1991; 151: 2212-16.
234. Menke-Pluymers MB, Hop WC, van Dees JBM, Tilanus HW. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 1993; 72: 1155-8.
235. Menke-Pluymers MB. Risk factors for neoplastic progression in Barrett's mucosa. Eur. J. Surg. Oncol. 1996; 22: 311-16.
236. Csendes A, Braghetto I, Burdiles P, Korn O. Roux-en-Y long limb diversion as the first option for patients who have Barrett's esophagus. Chest Surg. Clin. N. Am. 2002; 12: 157-84.
237. Csendes A, Smok G, Burdiles P, Braghetto I, Castro C, Korn O. Effect of duodenal diversion on low-grade dysplasia in patients with Barrett's esophagus. Analysis of 37 patients. J. Gastrointest. Surg. 2002; 6: 645-52.
238. Ell C, May A, Gossner L et al. Endoscopic mucosai resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118: 670-7.
239. Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J. Intramucosal adenocarcinoma arising under squamous reepithelialisation of Barrett's oesophagus. Gut 2000; 46: 574-7.
240. Walker SJ, Selvasekar CR, Birbeck N. Mucosal ablation in Barrett's esophagus. Dis. Esoph. 2002; 15: 22-9.
241. Sharma P, Bhattacharyya A, Garewal HS, Sampliner RE. Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus. Gastrointest. Endosc. 1999; 50: 159-64.
242. Byrne JP, Armstrong GR, Attwood SE. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am. J. Gastroenterol. 1998; 93: 1810-15.
243. Sampliner RE, Hixson LJ, Fennerty MB, Garewal HS. Regression of Barrett's esophagus by laser ablation in an anacid environment. Dig. Dis. Sci. 1993; 38: 365-8.
244. Sampliner RE, Faigei D, Fennerty MB et al. Effective and safe endoscopic reversal of nondyspiastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: A multicenter study. Gastrointest. Endosc. 2001; 53: 554-8.
245. Marshall RE, Manifold DK, Anggiansah A, Owen WJ. Management of Barrett's esophagus using combined laser ablation of the metaplastic mucosa combined with antireflux surgery. Ann. Surg. 1998; 228: 621-3.
246. McCarthy M, Wilkinson ML. Treatment of Barrett's esophagus by endoscopic laser ablation and antireflux surgery. Gastrointest. Endosc. 1999; 449: 129-30.
247. Montes CG, Brandalise NA, Deliza R, Novais dMA, Ferraz JG. Antireflux surgery followed by bipolar electrocoagulation in the treatment of Barrett's esophagus. Gastrointest. Endosc. 1999; 50: 173-7.
248. Salo JA, Salminen JT, Kiviluoto TA et al. Treatment of Barrett's esophagus by endoscopic laser ablation and antireflux surgery. Ann. Surg. 1998; 227: 40-4.
249. Wilkinson ML. Treatment of Barrett's esophagus by endoscopic laser ablation and antireflux surgery. Gastrointest. Endosc. 1999; 49: 129-30.